PPT-8: Anticoagulants Introduction about coagulation cascade

Classify drugs acting as anticoagulants Elaborate on their mechanism of action correlating that with methods of monitoring Contrast the limitations amp benefits of injectable anticoagulants in clinical settings. Prof . Khaled. . Yassen. MD FFARCSI. Department of . Anaesthesia. Liver Institute, . Menoufiya. University, Egypt.. kyassen61@hotmail.com. Old and New Liver Institute, . Menoufiya. University, Egypt. I-. Deficiency of Coagulation Factors. II-. HYPERCOAGULABLE STATES . I-. Deficiency of Coagulation Factors. Treatment. AQUIRED DISORDERS. OF. BLOOD COAGULATION. ACQUIRED DISORDERS. OF. BLOOD COAGULATION. Lupus Anticoagulant. General Approach of Haemostasis. Anti-. Phospholipids. antibodies.. Anti-. phospholipid. antibodies are a . heterogeneous. family of . autoantibodies. . that react with . epitopes. I-. Deficiency of Coagulation Factors. II-. HYPERCOAGULABLE STATES . I-. Deficiency of Coagulation Factors. Treatment. AQUIRED DISORDERS. OF. BLOOD COAGULATION. ACQUIRED DISORDERS. OF. BLOOD COAGULATION. Jonathan Carroll-Nellenback. Center for Integrated Research Computing. University of Rochester. Turbulence Workshop. August 4. th. 2015. Talk Outline. . Introduction to Turbulence in the context of gaseous flows. Fawaz Altuwaijri. ACEM trainee. Introduction. Characteristics . of novel . anticoagulants. Laboratory Testing. Reversal in the bleeding patient. Introduction. Prevalence . atrial fibrillation. . 3.03 million in 2005. Guy Young, MD. Children’s Hospital Los Angeles. University of Southern California Keck School of Medicine. Abbreviations. Abbreviations will be explained the first time the term appears on a slide. What are Direct-Acting Oral Anticoagulants DOACsANSWERS by heartTreatments TestscontinuedAdhere to your medication regimen and do not abruptly stop taking your DOACs without 31rst talking with your d Fibrin. Fibrinogen. Start with the bottom line: fibrin formation. After all, this is what the clotting cascade is designed for. Fibrin. Fibrinogen. 2 ways to get to bottom line:. Intrinsic pathway. Extrinsic pathway. :. are additives that inhibit clotting of blood and/or plasma. They act either by binding calcium ions or by inhibiting thrombin activity. . Platelets and coagulation factors are activated when blood vessels are punctured, and their activation continues in sample containers that do not contain anticoagulant, leads to clot formation which interfere with many analytical tests.. ?. That . major bleeding . occurs in about . 6.5% of patients on anticoagulants.. . That’s. . 1 patient in 15. . and commonly, GI Bleeding.. That . 1% . is . fatal bleeding . such as intracranial hemorrhage.. Edin. ). Haemostasis-blood must be maintained in a fluid state in order to function as a transport system, but must be able to solidify to form a clot following vascular injury in order to prevent excessive bleeding, a process known as haemostasis. It is localised to the tissue damage and is followed by removal of the clot and tissue damage.. ompueisedopeaorineraceforeaseofuse*PerectycompatilewithCascadeSysem*DualLoadforHigherAccuayAppliedAuomation ysems riae LimiedSF No 45, odissia oad, eelamedu oimbaoe - 641 004 IndiaPh +91 94430 3317, M. AND J. E. WYNANDS, M.D., C.IVI.~ THE V~Y F_~aLY STUVmS of this subject, many controversies existed regard- ing the various factors and mechanisms involved in the dotting process. One simply has to